Viracta Therapeutics, Inc.
VIRX · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.06 | 0.03 | -0.07 |
| FCF Yield | -77.46% | -48.90% | -17.98% | -45.35% |
| EV / EBITDA | -1.33 | -2.76 | -6.17 | -2.78 |
| Quality | ||||
| ROIC | -98.94% | -44.62% | -46.69% | -30.71% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 83.33% |
| Cash Conversion Ratio | 0.67 | 1.00 | 0.86 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 903,588.57% | 903,588.57% | 903,588.57% | 903,588.57% |
| Free Cash Flow Growth | 27.82% | -25.20% | 21.72% | 4.36% |
| Safety | ||||
| Net Debt / EBITDA | -0.39 | -0.54 | -0.83 | -1.04 |
| Interest Coverage | -15.00 | -13.76 | -16.17 | -14.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,205.63 | -1,973.45 | -1,751.83 |